BioTek Instruments Named ‘Vermont Business Growth Award’ Winner
News Aug 01, 2017
BioTek Instruments will be recognized as a 2017 Vermont Business Growth Award winner at a ceremony to be held September 12, 2017 at The Sheraton Hotel & Conference Center, in Burlington, VT. This award is sponsored by Vermont Business Magazine and KeyBank, and is presented to the five Vermont businesses that have experienced the greatest growth over the past five years in various business categories.
BioTek will be recognized as one of the winners in the Technology category for the company’s 28.3% growth over the past five years. This is the sixth time that the company has received this award.
“This award has particular meaning for us this year as we look forward to celebrating the company’s 50th anniversary,” commented BioTek’s President and CEO, Briar Alpert. “We are proud to continue to keep our headquarters, manufacturing, research and development, applications and service right here in Vermont and look forward to the years of growth ahead of us.”
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and distribution of innovative life science instrumentation. Our comprehensive product line includes cell imaging systems, microplate readers, washers, dispensers, automated incubators, stackers and pipetting systems. These products enable life science research by providing high performance, cost-effective analysis and quantification of biomolecules, biomolecular interactions and cellular structure and function across diverse applications. BioTek espouses a "Think Possible" approach that sets the tone for fresh ideas, unsurpassed customer service and original innovations.
ACD/Labs Collaboration Provides NMR Data to Brazilian Biodiversity Natural Products DatabaseNews
ACD/Labs announces collaboration with researchers at Brazilian Biodiversity database in support of chemical and pharmaceutical R&D.READ MORE
A Promising Framework for Predicting Drug Resistance in CancerNews
The system works by predicting the co-occurrence of about 500 known tumour alterations, as well as their response to over 200 common cancer drugs.READ MORE